In Hospital 24 Hour Observation of Syncope Patients
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jun 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "In Hospital 24 Hour Observation of Syncope Patients," is studying the best way to care for patients who experience syncope, which means fainting or temporary loss of consciousness. The trial is comparing two approaches: discharging patients right away or observing them for 24 hours in the hospital with monitoring. The goal is to find out if one method is safer or more effective than the other for patients who are considered low to intermediate risk for serious conditions.
To participate in this trial, patients should be between the ages of 65 and 74 and have been assessed as low or intermediate risk for serious issues related to their fainting episodes. Eligible patients will have a thorough check-up that includes discussing their medical history, a physical exam, and an electrocardiogram (ECG) to assess their heart. Participants can expect to stay in the hospital for 24 hours to be monitored if they are selected for that group, and they will be closely observed to ensure their safety. This trial aims to improve how doctors decide when it is safe for patients to go home after experiencing syncope.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients that are assessed as low- and intermediate risk syncope, are eligible for inclusion in this trial.
- The initial syncope evaluation includes:
- • 1. Complete and thorough history taking of the syncope event and past medical history
- • 2. Physical examination including supine and standing BP measurement and
- • 3. 12 lead ECG.
- Exclusion Criteria:
- A potential patient who meets any of the following criteria will be excluded from participation in this study:
- • 1. Those aged \<18 years
- • 2. Those in whom syncope / transient loss of consciousness co-exist with trauma or other serious condition identified in the CER (massive bleeding, pulmonary embolus) or any high-risk features upon assessment with guideline based SA
- • 3. Those with any other conditions then syncope / transient loss of consciousness for which admission is required (including social indication for admission, etc.)
- • 4. Contraindication for early discharge as the discretion of the responsible physician
- • 5. Those with a learning disability
- • 6. Those presenting with pre-syncope
- • 7. Those who are unwilling to provide informed consent (those will be asked to be enrolled for the SYNCOPE R.I.S.C-registry)
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Patients applied
Trial Officials
Frederik de Lange, MD PhD
Principal Investigator
PI
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported